The results from a phase 3 clinical trial evaluating Eli Lilly and Company's (NYSE: LLY) tirzepatide (10 mg and 15 mg) for chronic weight management in individuals with obesity or overweight and type 2 diabetes demonstrated superior weight reduction compared to the placebo for both dosage strengths.

Both the 10 mg and 15 mg doses of tirzepatide achieved significant weight reduction, with mean reductions of 13.4% and 15.7% respectively, surpassing the 3.3% reduction observed with the placebo. The trial also showed positive outcomes in key secondary endpoints, including reductions in waist circumference, fasting glucose levels, and improvements in blood pressure and lipid profiles.

These findings hold great significance for individuals with type 2 diabetes who have long struggled with excess weight. They often face greater difficulties in achieving weight loss, typically experiencing 30% less weight reduction compared to those with obesity but without diabetes. Consequently, there is a critical need for effective treatment options to address these challenges and facilitate substantial weight reductions.

According to W. Timothy Garvey, MD, MACE, MABOM, Professor of Medicine at the University of Alabama at Birmingham (UAB), Director of the UAB Diabetes Research Center and Principal Investigator of the trial, Eli Lilly's tirzepatide has demonstrated promise in meeting these unmet needs. Alongside enabling significant body weight reductions of up to 15.7%, tirzepatide has exhibited notable reductions in A1C levels without severe hypoglycemia, and it has shown improvements in other important cardiometabolic indicators.

These findings underscore the potential of Eli Lilly's tirzepatide as an encouraging treatment option for individuals with type 2 diabetes and obesity, providing hope for substantial weight loss and improved overall health outcomes.

Eli Lilly has concluded the submission of tirzepatide for FDA approval in chronic weight management, and regulatory action is anticipated by the end of 2023.

On Friday, $LLY closed at $458.84, up $1.16 (0.25%) 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)